NLRP3 and prostate carcinoma: Moreover, the study lacked functional validation, subgroup analysis by tumor grade or stage, and assessment of cytokine output, which limits its ability to capture the dynamic pro- or anti-tumor role of NLRP3 in prostate cancer (90).